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Context: The mechanism of action of metformin remains unclear. Given the regulation of the
cortisol-regenerating enzyme 11hydroxysteroid dehydrogenase 1 (11HSD1) by insulin and the
limited efficacy of selective 11HSD1 inhibitors to lower blood glucose when co-prescribed with
metformin, we hypothesized that metformin reduces 11HSD1 activity.
Objective: To determinewhethermetformin regulates 11HSD1 activity in vivo in obesemenwith
and without type 2 diabetes mellitus.
Design: Double-blind, randomized, placebo-controlled, crossover study.
Setting: A hospital clinical research facility.
Participants:Eightobesenondiabetic (OND)menandeightobesemenwith type2diabetes (ODM).
Intervention: Participants received 28 days ofmetformin (1 g twice daily), placebo, or (in the ODM
group) gliclazide (80mg twice daily) in random order. A deuterated cortisol infusion at the end of
each phase measured cortisol regeneration by 11HSD1. Oral cortisone was given to measure
hepatic 11HSD1activity in theODMgroup. Theeffectofmetforminon11HSD1wasalsoassessed
in human hepatocytes and Simpson-Golabi-Behmel syndrome adipocytes.
Main Outcome Measures: The effect of metformin on whole-body and hepatic 11HSD1 activity.
Results:Whole-body 11HSD1 activity was approximately 25%higher in the ODMgroup than the
OND group. Metformin increased whole-body cortisol regeneration by 11HSD1 in both groups
compared with placebo and gliclazide and tended to increase hepatic 11HSD1 activity. In vitro,
metformin did not increase 11HSD1 activity in hepatocytes or adipocytes.
Conclusions:Metformin increases whole-body cortisol generation by 11HSD1 probably through
an indirect mechanism, potentially offsetting othermetabolic benefits ofmetformin. Co-prescrip-
tion with metformin should provide a greater target for selective 11HSD1 inhibitors. (J Clin
Endocrinol Metab 101: 3787–3793, 2016)
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Metformin is the mainstay of treatment in obese pa-tients with type 2 diabetes mellitus (T2DM), yet
themechanismof action remains unclear.Metformin low-
ers glucose concentrations in part by suppressing hepatic
gluconeogenesis (1), an effect thought to be primarily me-
diated through inhibition of the respiratory-chain com-
plex Iwith subsequent activationofAMPK(2).Additional
mechanisms contributing to the glucose-lowering effect of
metformin have been proposed, such as the organic cation
transporterOct1,which enhances the actionofmetformin
in the liver, whereasmetforminmay antagonize the effects
of glucagon (reviewed in Ref. 3). A further potential mo-
lecular target for metformin action has been identified af-
ter the discovery of altered tissue cortisol regulation in
obesity and T2DM (4–6).
Although circulating cortisol is controlled centrally
by the hypothalamic-pituitary-adrenal (HPA) axis, tis-
sue glucocorticoid levels are further regulated by the
11-hydroxysteroid dehydrogenase (11HSD) enzymes.
The type2 isozyme(11HSD2)converts cortisol to inactive
cortisone, modulating activation of mineralocorticoid re-
ceptors in relevant tissues such as kidney (7). The type 1
isozyme (11HSD1) is more abundant across metaboli-
cally active tissues, particularly in the liver and adipose
tissue, and primarily converts cortisone to cortisol (8).
Transgenic mice overexpressing 11HSD1 in adipose tis-
sue or liver develop features of the metabolic syndrome
such as obesity, glucose intolerance, and dyslipidemia (9,
10). In human obesity, hepatic 11HSD1 activity is de-
creased whereas adipose tissue 11HSD1 is increased, re-
sulting in similar whole body cortisol regeneration by
11HSD1 compared to lean individuals (4, 5, 11). In con-
trast, in obesity-associated T2DM, cortisol regeneration
by 11HSD1 in the whole body is increased while hepatic
11HSD1 activity is unchanged compared with lean non-
diabetic individuals (6, 12); because insulin suppresses he-
patic 11-HSD1 activity (13), the impaired insulin signal-
ing associated with T2DM may drive the lack of
suppression of hepatic 11HSD1 in this group. These re-
sults highlight the potential benefit of inhibiting
11HSD1 as a novel treatment for obesity-associated
T2DM.
Numerous selective 11HSD1 inhibitors have been
developed (reviewed in Ref. 14); however, results from
the published phase 2 trials have been disappointing.
The vast majority of patients participating in these trials
were co-prescribed metformin. We hypothesized that
the improvement in insulin sensitivity induced by met-
formin may decrease hepatic 11HSD1 activity and
limit the efficacy of 11HSD1 inhibition. Therefore, we
tested whether metformin regulates cortisol regenera-
tion by 11HSD1 in obese individuals with T2DM (the
target group for selective 11-HSD1 inhibitors) and in
obese euglycemic individuals (who have suppressed
hepatic 11-HSD1 unlike those with T2DM), using a
deuterated cortisol infusion to measure whole-body
11HSD1 activity (15).
Subjects and Methods
In vivo study protocol
Eight obese nondiabetic (OND) men and eight obese men
with T2DM (ODM) were recruited to this double-blind, pla-
cebo-controlled crossover study. Inclusion criteria were: body
mass index (BMI) 30 kg/m2; age, 18–70 years; alcohol in-
take 21 U per week; no exogenous glucocorticoid exposure
in the preceding 6 months; normal screening blood tests (full
blood count, kidney, liver, and thyroid function, and normal
glucose in the OND group);5% change in body weight over
the preceding 3 months; not on any medications known to
regulate cortisol metabolism (eg, antifungals, 5-reductase inhib-
itors, or opiates); glycated hemoglobin (HbA1c) 10% (86
mmol/mol) if diet controlled or 8% (64 mmol/mol) if on
metformin monotherapy (ODM group only). Informed con-
sent was obtained from all participants, and approval was
obtained for this study from the local research ethics com-
mittee. ODM participants remained on their other prescribed
medications (eg, statins, antihypertensives) throughout the study.
Participants were randomized to receive 28 days of either pla-
cebo or metformin 1 g twice daily; to account for any confound-
ing effect of improving glycemic control on 11HSD1, theODM
group underwent a third phase taking the sulfonylurea gliclazide
80 mg twice daily. There was a 3-day washout period between
phases.
At the end of each phase, subjects attended the Clinical
Research Facility at 8:30 AM after an overnight fast. Measure-
ments of height and weight were performed, and baseline
blood samples were taken for fasting glucose, insulin, and
HbA1c. To measure whole-body 11HSD1 activity, cortisol
(containing 20% 9,11,12,12-[2H]4-cortisol [D4-cortisol];
Cambridge Isotopes) was infused at 1.74 mg/h for 4 hours
after an initial 3.5-mg bolus (16). In brief, D4-cortisol is converted
to 9,12,12-[2H]3-cortisone (D3-cortisone) by 11HSD2due to the
loss of the deuterium on the 11th carbon. D3-cortisone is then re-
generated to D3-cortisol by 11HSD1. Once in steady state, dilu-
tion of D4-cortisol by D3-cortisol is a specific measure of cortisol
regeneration by 11HSD1. Blood samples were taken at regular
intervals once steady state was achieved (t 150 minutes) (Figure
1). In theODMgroup, after samples had been collected for steady-
statemeasurements,oralcortisone(5mg)wasgivenat180minutes,
and conversion to cortisol was measured over the next hour to
determine hepatic 11HSD1 activity (6).
Effects of metformin on 11HSD1 activity in vitro
Human primary hepatocytes (Bioreclamation IVT) were
cultured according to the manufacturer’s instructions. Hu-
man Simpson-Golabi-Behmel syndrome preadipocytes were
cultured as previously described (17). Three days after plating
(hepatocytes) or after completion of differentiation on day 12
(adipocytes), cells were cultured for 24 hours in vehicle or 100
nM, 1 M, 10 M, 100 M, 1 mM, or 10 mM metformin hy-
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drochloride (Sigma). Thereafter, cells were incubated with
medium containing 1 M cortisone (enriched with 20 nM 1,2-
[3H]2-cortisone; GE Healthcare) for either 120 (hepatocytes)
or 240 minutes (adipocytes) at 37°C to measure conversion to
cortisol.
Laboratory analysis
Biochemical measurements
Plasma glucose was measured using a colorimetric assay
and insulin was measured by immunoassay using Abbott Ar-
chitect analysers. HbA1c was measured by HPLC (HA8180
analyzer, Menarini Diagnostics). Endogenous and tracer glu-
cocorticoids (cortisol, D4-cortisol, D3-cortisol, cortisone,
and D3-cortisone) were measured by liquid chromatography
tandem mass spectrometry as previously described (6).
Metformin and gliclazide were extracted from plasma
(100 L) using an SLE plate (Biotage) after enrichment with
D6-metformin and D3-glyburide as in-
ternal standards (200 ng). Calibration
standards ranged from 0.5–1000 ng.
Analytes were eluted, reduced to dry-
ness under nitrogen (40°C), and recon-
stituted in water/acetonitrile (100 L;
80:20, v/v). Analysis was carried out by
liquid chromatography tandem mass
spectrometry. Chromatographic sepa-
ration was on an ACE Excel
Super2C18 column (100  3 mm; 2
m) protected by a Kinetex Krud-
Katcher (Phenomenex) and detected on
a 5500 QTrap (Seiex) operated by se-
lective reaction monitoring in positive
electrospray ionization mode. The mo-
bile phase was 0.1% formic acid in wa-
ter (A) and 0.1% formic acid in aceto-
nitrile (B) at 0.2 mL/min and 30°C.
Gradient elution was from 20–90% in
B,wheremetformin andD6-metformin
eluted at 1.1minutes and gliclazide and
D3-glyburide eluted at 2.0 and 2.3min-
utes, with a total run time of 5 minutes.
Transitions monitored for were m/z
130.13 60.1 andm/z 136.23 60.1 for
metformin and D6-metformin, respec-
tively, andm/z 324.23 153.1 andm/z
497.13 372.1, for gliclazide andD3-gly-
buride, respectively.
Analysis of tritiated steroids
Tritiated steroids were extracted
from 200 L of medium using metha-
nol. [3H]2-Cortisone and [
3H]2-corti-
sol were quantified by HPLC with on-
line -scintillation counting (Berthold
LB509 detector; Berthold Technolo-
gies). Samples were analyzed in qua-
druplicate. Total proteinwasmeasured
in each sample using the DC protein
assay (Bio-Rad), and cortisol produc-
tion rates were normalized for protein
content.
Cortisol kinetics
Cortisol kinetics were calculated as previously described
(6). Steady-state samples were collected from 150 to 240 min-
utes in the OND group and from 150 to 180 minutes (time of
cortisone ingestion) in the ODM group. Rate of appearance
(Ra) of endogenous cortisol in the whole body during steady
state was calculated using Equation 1:
Ra Cortisol 
D4-Cortisol infusion rate
D4-Cortisol Cortisol ratio rate
 Cortisol infusion rate (1)
RaD3-cortisol (a specificmeasure of cortisol regeneration by
11HSD1) was calculated using Equation 2:
Ra D3-Cortisol 
D4-Cortisol infusion rate
D4-Cortisol/D3-Cortisol ratio
(2)
Figure 1. Endogenous and tracer cortisol measurements. Data are expressed as mean  SEM
for metformin (black squares), gliclazide (open triangles), and placebo (open circles). A and D,
Plasma cortisol; B and E, D4-cortisol enrichment; C and F, D4-cortisol/D3-cortisol ratio in OND
(n  8; A–C) and ODM (n  8; D–F) groups.
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Clearance of D4-cortisol was calculated by dividing the D4-
cortisol infusion rate by the steady state D4-cortisol concentra-
tion. The Ra of cortisol after oral cortisone ingestion (a measure
of hepatic 11HSD1 activity) in the ODMgroupwas calculated
using Steele’s non-steady state equation (Equation 3) where t
denotes time, V is the volume of distribution, C(t) is the total
cortisol concentration at time (t), and E(t) is the tracer to tracee
ratio (D4 cortisol/cortisol). The volume of distribution for cor-
tisol was taken as being 12 L, as in previous studies (12, 18).
Ra Cortisol  D4-Cortisol infusion rateE(t) 
V 
C(t)
1  E(t)

dE(t)
dt
E(t)  (3)
Statistical analysis
Data are presented as mean SEM. Power calculations were
performed using prior data indicating that the difference in the
response of matched pairs was normally distributed with stan-
dard deviation 1.21 (16). Eight subjects per group provided
85%power to detect a 10%difference in theRa ofD3-cortisol
with a 0.05 probability of a type I error associated with this test.
Datawere analyzed using SPSS version 21 (SPSS, Inc). Datawere
normally distributed using Kolmogorov-Smirnov testing. Com-
parisons between two related samples were performed using
paired t tests and between three or more related samples using
repeated measures ANOVA with post hoc Fisher’s least signif-
icance difference (LSD) testing. Comparisons between two un-
related samples were performed using unpaired t tests. P  .05
was considered significant.
Results
Anthropometric and biochemical data
Subjects in the ODM group were older and had higher
fasting glucose and HbA1c than the OND participants
(Table 1). BMI was not different between the two groups
(P .2), and body weight did not change between phases
(data not shown). One of the OND subjects developed
transient diarrhea during the metformin phase. No other
side effects were reported by any of the participants. Met-
forminandgliclazidedecreased fasting glucose to a similar
extent in the ODM group, with similar trends in HbA1c,
but metformin did not alter fasting glucose in OND par-
ticipants (Table 1). Metformin and gliclazide were only
detected in the plasmaduring the appropriate phases (data
not shown).
Cortisol kinetics
Fasting cortisol was similar between OND and ODM
groupsandwasunalteredbymetforminorgliclazide treat-
ment (Figure 1, A and D).
Steady-state measurements
Steady-stateD4-cortisol enrichmentwas achieved after
150minutesofD4-cortisol infusion inbothgroups (Figure
1,BandE).Metformin increased theRaofD3-cortisol (Ra
D3-cortisol, a specific measure of whole-body 11HSD1
activity) compared with placebo (both groups) and glicla-
zide (ODM group only) (Figure 2B). Ra D3-cortisol was
higher inODMcomparedwithONDparticipants.TheRa
of cortisol (Figure 2A) and rate of D4-cortisol clearance
(Table 1) were unaltered by either treatment andwere not
different between ODM and OND groups.
Non-steady-state measurement of hepatic 11HSD1
activity
Cortisol production by hepatic 11HSD1 was calcu-
lated using Equation 3 in the ODM group. Metformin
tended to increaseRacortisol after oral cortisone (P .07)
(Figure 2C).
Effect of metformin on 11HSD1 activity in vitro
[3H]2-Cortisol was readily detected in all samples after
incubation. Metformin did not increase the conversion of
Table 1. Anthropometric and Biochemical Data
OND ODM
Placebo Metformin Placebo Metformin Gliclazide
Age, y 43.6  4.6 43.6  4.6 65.8  0.8b 65.8  0.8 65.8  0.8
BMI, kg/m2 37.4  2.6 37.3  2.8 34.2  1.1 34.2  1.2 34.6  1.1
Fasting glucose, mmol/L 5.6  0.6 5.3  0.2 10.8  1.0b 7.7  0.5a 7.0  0.6a
HbA1c, %/mmol/mol 5.7  0.2
(38.8  2.0)
5.7  0.2
(38.4  2.2)
7.2  0.2
(55.4  2.5)c
6.9  0.3
(52.4  3.0)
7.1  0.3
(53.6  3.6)
Fasting insulin, mU/L 17.1  5.1 10.6  2.2 24.2  9.7 24.9  10.3 21.4  7.5
HOMA-IR 5.0  1.9 2.5  0.6 9.4  3.2 7.0  2.2 7.2  1.7
Total cholesterol, mmol/L 4.5  0.4 4.7  0.6 3.5  0.2b 3.4  0.2 3.4  0.2
D4-Cortisol clearance, L/min 0.5  0.1 0.6  0.1 0.5  0.1 0.5  0.1 0.6  0.1
Abbreviation: HOMA-IR, homeostasis model of assessment for insulin resistance. Data are expressed as mean  SEM for data from OND (n  8)
and ODM (n  8) participants. Phases were compared using paired t tests in the OND group and repeated measures ANOVA with post hoc Fisher’s
LSD testing in the ODM group. Placebo-phase data for OND and ODM groups were compared using unpaired t tests.
a P  .05 vs placebo; b P  .05; c P  .01 vs OND group.
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[3H]2-cortisone to [
3H]2-cortisol in either the hepatocytes
or the adipocytes (Figure 3). In both the hepatocytes and
adipocytes, the highest metformin concentration (10 mM)
decreased cortisol generation by 11HSD1.
Discussion
Contrary to our hypothesis, metformin increased whole-
body cortisol regeneration by 11HSD1 in obese men
with and without T2DM. This substantial increase in Ra
D3-cortisol (	15%) in both groups suggests that the liver
is the most likely tissue responsible
because the liver accounts for90%
of extra-adrenal cortisol production
(8, 19). Furthermore, metformin
tended to increase conversion of
orally administered cortisone to cor-
tisol (ameasure of hepatic 11HSD1
activity) in the ODM group; in one
individual, there was, surprisingly,
no increase in either circulating corti-
soneorcortisolconcentrationsafteroral
cortisone ingestion, and removal of this
subject’s data led to a strongly signifi-
cant increase in hepatic cortisol genera-
tion on the metformin phase in the re-
maining seven subjects (P  .01).
Adipose tissue and skeletal muscle are
alternative tissues that could be respon-
sible, but this isunlikely because the in-
crease in Ra D3-cortisol induced by
metformin is greater than the contri-
bution of both tissues combined to
whole-body cortisol regeneration un-
der normal conditions (20).
In addition, we have determined
that whole-body 11HSD1 activity
is increased in ODMmen compared
to OND men. There have been conflicting results from
previous work examining whether hepatic and whole-
body 11HSD1 activity is altered in T2DM (6, 12, 21);
however, these results are consistent with the interpreta-
tion that hepatic 11HSD1 is decreased in euglycemic
obesity but not in obesity-associated T2DM (4, 22). Al-
though the ODM group was older, which could be a
potential confounder, we have not observed any in-
crease in cortisol regeneration by 11HSD1 with age in
previous studies (6, 16).
We hypothesized that insulin could mediate the effect of
metformin on 11HSD1 because insulin decreases hepatic
activity (13). Although it is possible
that metformin may have reduced in-
sulin levels in the OND group, there
was no suggestion of metformin re-
ducing insulin concentrations in the
ODM group, so it is unlikely that in-
sulin drives this regulation, whereas if
changes in insulin sensitivity were re-
sponsiblewemayhave expected to see
a greater effect in the ODM group.
Similarly, alterations in glucose con-
centrations are not responsible be-
cause levels were similar during the
gliclazide phase without altering
Figure 2. The effect of metformin on 11HSD1 activity in vivo. Data are expressed as mean 
SEM for the effect of metformin (black columns), gliclazide (bricked columns), and placebo
(white columns) on the Ra of cortisol (A) and D3-cortisol (B) during steady state. C, The effect of
metformin (black squares), gliclazide (open triangles), and placebo (open circles) on Ra cortisol
after 5 mg oral cortisone ingestion in the ODM group. Phases were compared using paired t tests
in the OND group and repeated measures ANOVA with post hoc Fisher’s LSD testing in the ODM
group. Placebo-phase data in OND and ODM groups were compared using the unpaired t test.
*, P  .05 vs placebo; $, P  .05 vs metformin; #, P  .05 vs OND group.
Figure 3. The effect of metformin on 11HSD1 activity in vitro. Data are expressed as mean 
SEM for the rate of cortisol production in primary human hepatocytes (A) and human Simpson-
Golabi-Behmel syndrome adipocytes (B) after incubation with vehicle (white columns) or
increasing doses of metformin (black columns) for 24 hours (n  4 per concentration).
Comparisons were performed using repeated measures ANOVA with post hoc Fisher’s LSD
testing. *, P  .05 vs vehicle.
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11HSD1 activity. Our in vitro data suggest that this is not
a direct effect, although it is possible that longer incubations
may have increased cortisol generation by 11HSD1. Cir-
culating metformin concentrations are typically 10–40
M in humans (23), whereas hepatic concentrations can
reach 100–200 M in rodents (24), meaning our in vitro
metformin concentrations encompassed the physiologi-
cally relevant range. It is possible that the reduction in
cortisol conversionat thehighest concentrationwasdue to
cytotoxicity because metformin has been reported as cy-
totoxic in the millimolar range, although this is supra-
physiological (25).
Recent work has shown that metformin decreases
ACTH secretion in humans (26) and reduces ACTH-stim-
ulated adrenal secretion (27). This is consistent with our
observation of enhanced peripheral regeneration of cor-
tisol and hence increased negative feedback to the HPA
axis; conversely, inhibition of 11HSD1 results in ele-
vated ACTH (14). However, we did not confirm a reduc-
tion in the clearance of cortisol or a decrease in total (ad-
renal plus11HSD1) cortisol productionwithmetformin,
although these may be more insensitive measurements.
Our initial hypothesis was that suppression of
11HSD1 activity by metformin could be the reason for
the lack of efficacy of selective 11HSD1 inhibitors in
improving HbA1c (14). However, metformin increased
11HSD1 activity, an effect that could offset the other
metabolic benefits of metformin and potentially enhance
any benefit of 11HSD1 inhibitors. Therefore, this does
not appear to be a reason for the lack of efficacy of these
drugs.
In conclusion, metformin increases whole-body and
likely hepatic regeneration of cortisol by 11HSD1 in
obese men with and without T2DM, so that co-prescrip-
tion ofmetforminwith selective 11HSD1 inhibitorsmay
maximize the metabolic benefits of these agents.
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